

# Accepted Manuscript

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma

Leslie Padrnos, Brenda Ernst, Amylou C. Dueck, Heidi E. Kosiorek, Brenda F. Ginos, Angela Toro, Patrick B. Johnston, Thomas M. Habermann, Jose F. Leis, Joseph R. Mikhael, Grzegorz S. Nowakowski, Joseph Colgan, Luis Porrata, Stephen M. Ansell, Thomas E. Witzig, Craig Reeder, MD

PII: S2152-2650(18)30335-5

DOI: [10.1016/j.clml.2018.06.013](https://doi.org/10.1016/j.clml.2018.06.013)

Reference: CLML 1140

To appear in: *Clinical Lymphoma, Myeloma and Leukemia*


Received Date: 4 April 2018

Revised Date: 3 June 2018

Accepted Date: 11 June 2018

Please cite this article as: Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C, A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: 10.1016/j.clml.2018.06.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



**A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients with Heavily Pretreated Relapsed Lymphoma**

Leslie Padrnos<sup>1</sup>, Brenda Ernst<sup>2</sup>, Amylou C. Dueck<sup>3</sup>, Heidi E. Kosiorek<sup>3</sup>, Brenda F. Ginos<sup>3</sup>, Angela Toro<sup>1</sup>, Patrick B Johnston<sup>4</sup>, Thomas M. Habermann<sup>4</sup>, Jose F. Leis<sup>1</sup>, Joseph R. Mikhael<sup>1</sup>, Grzegorz S. Nowakowski<sup>4</sup>, Joseph Colgan<sup>4</sup>, Luis Porrata<sup>4</sup>, Stephen M. Ansell<sup>4</sup>, Thomas E. Witzig<sup>4</sup>, Craig Reeder MD<sup>1</sup>

1 Mayo Clinic Arizona, Hematology Oncology

2 Mayo Clinic Jacksonville, Hematology Oncology

3 Mayo Clinic Arizona, Research Biostatistics

4 Mayo Clinic, Hematology

Corresponding Author:

Dr. Craig Reeder

5777 East Mayo Boulevard

Phoenix, Arizona 85054

[Reeder.Craig@mayo.edu](mailto:Reeder.Craig@mayo.edu)

**Short Title: Phase 1/2 trial everolimus and lenalidomide in relapsed lymphoma**

Keywords: everolimus, lenalidomide, phase 1, phase 2, relapsed lymphoma

**Financial Support**

This study was provided financial support from Celgene and Novartis.

L. Padrnos, B. Ernst, A. Dueck, H. Kosiorek, B. Ginos, A. Toro, T. Haberman, S. Ansell, P. Johnson, J. Leis, J. Colgan, L. Porrata report no financial support and no conflicts of interest.

J. Mikhael receives research funding from Abbvie, Celgene, and Sanofi.

C. Reeder and T. Witzig received research funding from Celgene and Novartis regarding this study.

G. Nowakowski receives research support from Celgene, Morphosys, Roche, Janseen, Seattle Genetics and Bayer. He is a consultant for Morphosys. He is on the Advisory Board for Celgene, Roche, Janseen, Seattle Genetics and Bayer.

**Summary**

Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable in most patients. Everolimus (RAD) and lenalidomide (LEN) have shown clinical activity as single agents in patients with relapsed and refractory (R/R) Hodgkin and non-Hodgkin lymphomas. This Phase I/II trial

Download English Version:

<https://daneshyari.com/en/article/10211917>

Download Persian Version:

<https://daneshyari.com/article/10211917>

[Daneshyari.com](https://daneshyari.com)